Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Thomas J. Steenburgh"'
Publikováno v:
SSRN Electronic Journal.
Publikováno v:
Journal of Marketing Research. 56:652-665
Sales leaders often use threats of punishment to manage poor performers (i.e., laggards), but little research has examined the effect of these threats. The current research addresses this gap by investigating an intervention termed the “bench progr
Publikováno v:
Management Science. 64:2473-2495
We study how digital service firms can develop an active customer base, focusing on two questions. First, how does the way that customers use the service postadoption to meet their own needs (personal usage) and to interact with one another (social u
Publikováno v:
Journal of Accounting Research. 54:1233-1266
We surveyed 1,638 sales executives across 40 countries regarding their companies' likelihood of asking sales to perform real earnings management (REM) actions when earnings pressure exists. Using this information, which we refer to as companies' REM
Autor:
Paul M. Hammaker, Thomas J. Steenburgh
Publikováno v:
Darden Business Publishing Cases. :1-9
This case examines the public controversy that erupted over the increasingly high price of EpiPens. Mylan Inc. (Mylan), a generic drug maker, bought the EpiPen product line from Merck in 2007. Since that time, the company both invested in marketing t
Publikováno v:
SSRN Electronic Journal.
Cohort-level retention rates typically increase over time, and the beta-geometric (BG) distribution has proven to be a robust model for capturing and projecting these patterns into the future. According to this model, the phenomenon of increasing coh
Publikováno v:
Marketing Science. 34:144-159
Different objectives such as category demand expansion or market share stealing warrant the use of different marketing instruments. To help brand managers make informed decisions, it is essential that marketing mix models appropriately measure their
Publikováno v:
SSRN Electronic Journal.
Publikováno v:
SSRN Electronic Journal.
Autor:
Thomas J. Steenburgh
Publikováno v:
SSRN Electronic Journal.
This case examines the public controversy that erupted over the increasingly high price of EpiPens. Mylan Inc. (Mylan), a generic drug maker, bought the EpiPen product line from Merck in 2007. Since that time, the company both invested in marketing t